Infection-induced inflammatory response of adipocytes in vitro

International Journal of Obesity

Volumn 32, Issue 6, 2008, Pages 892-901

  Bouwman, J J M ^a   Visseren, F L J ^b   Bouter, K P ^c   Diepersloot, R J A ^a  

^a DEPARTMENT OF SURGERY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

Adenovirus; Adipocytes; IL 6; Infection; TNF

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ADENOVIRUS; ADIPOCYTE; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DIABETES MELLITUS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION; INFLAMMATION; INFLUENZA VIRUS A; INSULIN RESISTANCE; PRIORITY JOURNAL; PROADIPOCYTE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STATISTICAL ANALYSIS;

ABDOMINAL FAT; ADENOVIRUS INFECTIONS, HUMAN; ADIPOCYTES; ADIPONECTIN; ATHEROSCLEROSIS; CELLS, CULTURED; CHLAMYDOPHILA INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; DIABETES MELLITUS; HUMANS; INFLUENZA, HUMAN; INTERLEUKIN-6; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; RICE STRIPE VIRUS;

EID: 47249115257     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2008.36     Document Type: Article

References (54)

1. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
2. Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep 2004; 1: 63-68.
3. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005; 46: 1978-1985.
4. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003; 52: 1799-1805.
5. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137.
6. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
7. Festa A, D'Agostino Jr R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001; 25: 1407-1415.
8. Gasteyger C, Tremblay A. Metabolic impact of body fat distribution. J Endocrinol Invest 2002; 25: 876-883.
9. Bouwman JJ, Visseren FL, Bevers LM, van der Vlist WE, Bouter KP, Diepersloot RJ. Azithromycin reduces Chlamydia pneumoniae-induced attenuation of eNOS and cGMP production by endothelial cells. Eur J Clin Invest 2005; 35: 573-582.
10. Bouwman JJ, Visseren FL, Bosch MC, Bouter KP, Diepersloot RJ. Procoagulant and inflammatory response of virus-infected monocytes. Eur J Clin Invest 2002; 32: 759-766.
11. Campbell LA, Kuo CC. Chlamydia pneumoniae - an infectious risk factor for atherosclerosis? Nat Rev Microbiol 2004; 2: 23-32.
12. Grayston JT, Kuo CC, Campbell LA, Benditt EP. Chlamydia pneumoniae, strain TWAR and atherosclerosis. Eur Heart J 1993; 14 (Suppl K): 66-71.
13. Visseren FL, Bouwman JJ, Bouter KP, Diepersloot RJ, de Groot PH, Erkelens DW. Procoagulant activity of endothelial cells after infection with respiratory viruses. Thromb Haemost 2000; 84: 319-324.
14. Zhu J, Quyyumi AA, Norman JE, Csako G, Epstein SE. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol 1999; 34: 1738-1743.
15. Dhurandhar NV. Contribution of pathogens in human obesity. Drug News Perspect 2004; 17: 307-313.
16. Whigham LD, Israel BA, Atkinson RL. Adipogenic potential of multiple human adenoviruses in vivo and in vitro in animals. Am J Physiol Regul Integr Comp Physiol 2006; 290: R190-R194 e-pub.
17. Desruisseaux MS, Trujillo ME, Trujillo ME, Tanowitz HB, Scherer PE. Adipocyte, adipose tissue, and infectious disease. Infect Immun 2007; 75: 1066-1078.
18. Dhurandhar NV. Infectobesity: obesity of infectious origin. J Nutr 2001; 131: 2794S-2797S.
19. Dhurandhar NV, Whigham LD, Abbott DH, Schultz-Darken NJ, Israel BA, Bradley SM et al. Human adenovirus Ad-36 promotes weight gain in male rhesus and marmoset monkeys. J Nutr 2002; 132: 3155-3160.
20. Dhurandhar NV, Israel BA, Kolesar JM, Mayhew G, Cook ME, Atkinson RL. Transmissibility of adenovirus-induced adiposity in a chicken model. Int J Obes Relat Metab Disord 2001; 25: 990-996.
21. Dhurandhar NV, Israel BA, Kolesar JM, Mayhew GF, Cook ME, Atkinson RL. Increased adiposity in animals due to a human virus. Int J Obes Relat Metab Disord 2000; 24: 989-996.
22. Atkinson RL, Dhurandhar NV, Allison DB, Bowen RL, Israel BA, Albu JB et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes (Lond) 2005; 29: 281-286.
23. Reed LJ, Muench J. A simple method for estimating fifty percent endpoints. Am J Hyg 27; 493: 1938. ref type: Generic.
24. Bouwman JJ, Visseren FL, Bouter PK, Diepersloot RJ. Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae. J Lab Clin Med 2004; 144: 18-26.
25. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138 (5 Part 2): S419-S420.
26. Altman R. Risk factors in coronary atherosclerosis atheroinflammation: the meeting point. Thromb J 2003; 1: 4.
27. Wu JT, Wu LL. Linking inflammation and atherogenesis: soluble markers identified for the detection of risk factors and for early risk assessment. Clin Chim Acta 2006; 366: 74-80.
28. Erdmann E. Diabetes and cardiovascular risk markers. Curr Med Res Opin 2005; 21 (Suppl 1): S21-S28.
29. Basta G, Schmidt AM, De CR. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-592.
30. de Larranaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 2003; 110: 93-98.
31. Leinonen M, Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2002; 2: 11-17.
32. Muhlestein JB. Infectious agents, antibiotics, and coronary artery disease. Curr Interv Cardiol Rep 2000; 2: 342-348.
33. Cannon CP, Braunwald E, Mccabe CH, Grayston JT, Muhlestein B, Giugliano RP et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646-1654.
34. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-356.
35. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997; 96: 2144-2148.
36. Watt S, Aesch B, Lanotte P, Tranquart F, Quentin R. Viral and bacterial DNA in carotid atherosclerotic lesions. Eur J Clin Microbiol Infect Dis 2003; 22: 99-105.
37. Dhurandhar NV, Kulkarni PR, Ajinkya SM, Sherikar AA, Atkinson RL. Association of adenovirus infection with human obesity. Obes Res 1997; 5: 464-469.
38. So PW, Herlihy AH, Bell JD. Adiposity induced by adenovirus 5 inoculation. Int J Obes (Lond) 2005; 29: 603-606.
39. Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 1999; 99: 2221-2222.
40. Esteve E, Castro A, Lopez-Bermejo A, Vendrell J, Ricart W, Fernandez-Real JM. Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care 2007; 30: 939-945.
41. Paik JK, Kim OY, Koh SJ, Jang Y, Chae JS, Kim JY et al. Additive effect of interleukin-6 and C-reactive protein (CRP) single nucleotide polymorphism on serum CRP concentration and other cardiovascular risk factors. Clin Chim Acta 2007; 380: 68-74.
42. Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Douvdevani A et al. Raised interleukin-6 levels in obese patients. Obes Res 2000; 8: 673-675.
43. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52: 2784-2789.
44. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25: 2062-2068.
45. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214.
46. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
47. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992; 52: 4113-4116.
48. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280: E827-E847.
49. Rathod M, Vangipuram SD, Krishnan B, Heydari AR, Holland TC, Dhurandhar NV. Viral mRNA expression but not DNA replication is required for lipogenic effect of human adenovirus Ad-36 in preadipocytes. Int J Obes (Lond) 2007; 31: 78-86.
50. Vangipuram SD, Sheele J, Atkinson RL, Holland TC, Dhurandhar NV. A human adenovirus enhances preadipocyte differentiation. Obes Res 2004; 12: 770-777.
51. Knorr CW, Allen SD, Torres AR, Smee DF. Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection. Antiviral Res 2006; 72: 125-133.
52. Chung S, Lapoint K, Martinez K, Kennedy A, Boysen SM, McIntosh MK. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology 2006; 147: 5340-5351.
53. Hube F, Lee YM, Rohrig K, Hauner H. The phosphodiesterase inhibitor IBMX suppresses TNF-alpha expression in human adipocyte precursor cells: a possible explanation for its adipogenic effect. Horm Metab Res 1999; 31: 359-362.
54. Harkins JM, Moustaid-Moussa N, Chung YJ, Penner KM, Pestka JJ, North CM et al. Expression of interleukin-6 is greater in preadipocytes than in adipocytes of 3T3-L1 cells and C57BL/6J and ob/ob mice. J Nutr 2004; 134: 2673-2677.